Flat dispensing fees and ingredient cost payments are not barred
What the document says“prohibiting flat dispensing fees or reimbursement or payment for ingredient costs (including customary, industry-standard discounts directly related to drug acquisition that are retained by pharmacies or wholesalers) to entities that acquire or dispense prescription drugs; or”
The new subsection states that nothing in it bars flat dispensing fees or payment for ingredient costs, including customary industry-standard discounts related to drug acquisition kept by pharmacies or wholesalers, and that nothing in it changes regulatory or subregulatory requirements on pharmacy payment, reimbursement or dispensing fees.
What the document actually says“prohibiting flat dispensing fees or reimbursement or payment for ingredient costs (including customary, industry-standard discounts directly related to drug acquisition that are retained by pharmacies or wholesalers) to entities that acquire or dispense prescription drugs; or”
Nothing here bars a flat fee for filling a prescription. Nothing here bars paying a pharmacy back for what a drug cost it.
The rules above are aimed at the middleman. A pharmacy still has to be paid for its work and its stock. This says so plainly.
No action is recorded against this proposal. That is not evidence that none has been taken, and nobody has yet read it against the record. See what the tracker does not yet cover.